Literature DB >> 12700694

Selective antagonism at dopamine D3 receptors prevents nicotine-triggered relapse to nicotine-seeking behavior.

Michela Andreoli1, Michela Tessari, Maria Pilla, Enzo Valerio, Jim J Hagan, Christian A Heidbreder.   

Abstract

Drugs of abuse, including, nicotine have been shown to enhance brain reward functions in the mesocortico-limbic dopamine (DA) system in general, and the nucleus accumbens in particular. The latter occupies a prominent position in the ventral striatum and expresses a high density of DA D(3) receptors. As such, the present study aimed at investigating the effect of the selective D(3) receptor antagonist SB-277011-A on both the stable maintenance of intravenous nicotine self-administration and nicotine-triggered relapse to nicotine-seeking behavior in the rat. SB-277011-A (3-10 mg/kg i.p.) significantly reduced reinstatement of nicotine-seeking behavior without affecting nicotine self-administration per se. These results suggest that DA D(3) receptors are involved in the reinstatement of nicotine-seeking behavior independently of any interaction with the primary reinforcing effects of nicotine itself. These findings point toward the potential use of selective DA D(3) receptor antagonists for the pharmacotherapeutic management of relapse to drug-seeking behaviors.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12700694     DOI: 10.1038/sj.npp.1300183

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  51 in total

1.  Galantamine, an acetylcholinesterase inhibitor and positive allosteric modulator of nicotinic acetylcholine receptors, attenuates nicotine taking and seeking in rats.

Authors:  Thomas J Hopkins; Laura E Rupprecht; Matthew R Hayes; Julie A Blendy; Heath D Schmidt
Journal:  Neuropsychopharmacology       Date:  2012-06-06       Impact factor: 7.853

2.  The selective dopamine D3 receptor antagonist SB-277011A reduces nicotine-enhanced brain reward and nicotine-paired environmental cue functions.

Authors:  Arlene C Pak; Charles R Ashby; Christian A Heidbreder; Maria Pilla; Jeremy Gilbert; Zheng-Xiong Xi; Eliot L Gardner
Journal:  Int J Neuropsychopharmacol       Date:  2006-08-31       Impact factor: 5.176

Review 3.  Complex interactions between nicotine and nonpharmacological stimuli reveal multiple roles for nicotine in reinforcement.

Authors:  Nadia Chaudhri; Anthony R Caggiula; Eric C Donny; Matthew I Palmatier; Xiu Liu; Alan F Sved
Journal:  Psychopharmacology (Berl)       Date:  2005-10-21       Impact factor: 4.530

4.  Effects of isoarecolone, a nicotinic receptor agonist in rodent models of nicotine dependence.

Authors:  Mohammed Shoaib
Journal:  Psychopharmacology (Berl)       Date:  2006-08-24       Impact factor: 4.530

Review 5.  The role of central dopamine D3 receptors in drug addiction: a review of pharmacological evidence.

Authors:  Christian A Heidbreder; Eliot L Gardner; Zheng-Xiong Xi; Panayotis K Thanos; Manolo Mugnaini; Jim J Hagan; Charles R Ashby
Journal:  Brain Res Brain Res Rev       Date:  2005-07

Review 6.  [Future medications for tobacco and cannabis dependence].

Authors:  Bernard Le Foll; Zuzana Justinova; Gianlugi Tanda; Steven R Goldberg
Journal:  Bull Acad Natl Med       Date:  2008-01       Impact factor: 0.144

7.  Blockade of mesolimbic dopamine D3 receptors inhibits stress-induced reinstatement of cocaine-seeking in rats.

Authors:  Zheng-Xiong Xi; Jeremy Gilbert; Arlene C Campos; Nicole Kline; Charles R Ashby; Jim J Hagan; Christian A Heidbreder; Eliot L Gardner
Journal:  Psychopharmacology (Berl)       Date:  2004-04-09       Impact factor: 4.530

8.  The selective dopamine D3 receptor antagonists SB-277011A and NGB 2904 and the putative partial D3 receptor agonist BP-897 attenuate methamphetamine-enhanced brain stimulation reward in rats.

Authors:  Krista Spiller; Zheng-Xiong Xi; Xiao-Qing Peng; Amy H Newman; Charles R Ashby; Christian Heidbreder; József Gaál; Eliot L Gardner
Journal:  Psychopharmacology (Berl)       Date:  2007-11-06       Impact factor: 4.530

9.  The alpha4beta2 nicotinic acetylcholine-receptor partial agonist varenicline inhibits both nicotine self-administration following repeated dosing and reinstatement of nicotine seeking in rats.

Authors:  Eoin C O'Connor; Dale Parker; Hans Rollema; Andy N Mead
Journal:  Psychopharmacology (Berl)       Date:  2009-12-05       Impact factor: 4.530

Review 10.  Effects of nicotine in experimental animals and humans: an update on addictive properties.

Authors:  Bernard Le Foll; Steven R Goldberg
Journal:  Handb Exp Pharmacol       Date:  2009
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.